Oceanium has highlighted that Armenjon brings extensive experience of commercialisation of novel ingredients. The company believes he will be instrumental in taking them to full-scale commercialisation, securing Series A funding and scaling of their proprietary seaweed biorefinery. Armenjon joins from Ÿnsect, where he led the sales and commercialisation side of the insect business.
Oceanium has stated that it marks a significant step in their mission to provide efficacious, functional, and clean label seaweed-based ingredients with excellent traceability and provenance, whilst contributing to human and ocean health.
About Benjamin Armenjon
Armenjon has run sales and business development in an international capacity across food, feed, and fertiliser sectors. Before joining Oceanium, Armenjon was chief sales and development officer and general manager for nutrition and health at insect producer Ÿnsect, one of Europe's leading companies in scaling alternative ingredients. There he supported its international growth and expansion to over 300 people, with sites across Europe and the US.
Karen Scofield Seal, co-founder and CEO of Oceanium, stated in a press release: “Benjamin Armenjon has already been on the journey from start-up to scale-up to industry leader and can bring this invaluable experience to Oceanium. This appointment marks a pivotal moment for Oceanium, and we are excited about the transformative impact that Benjamin will bring to the team, with a focus on scaling our proprietary seaweed biorefinery technology and launching Oceanium’s next-gen seaweed products to market.”
Armenjon added: “I am really delighted to be joining Oceanium at this exciting stage of its growth. The company has already made significant progress on developing its ingredients and proving its biorefinery technology, and I am looking forward to being part of this skilled, passionate team to scale up and deliver real change.”